Verastem is evolving from a speculative biotech into a commercially validated precision oncology com

Shares of Verastem, Inc. (NASDAQ: VSTM - Get Free Report) have earned a consensus rating of "Moderat

Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers th

Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales o

Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the pri

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimat

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.35) per share which beat the analyst consens

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 203, a registration

Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

TARGET-D 202 (NCT07659782) is a global, open-label, Phase 2 registration-directed trial evaluating V

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 202, a registration

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cance

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonst

Verastem, Inc. is maintained at a Buy rating, driven by upcoming clinical catalysts and positive ear

Verastem, Inc. (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive

Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and con

90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis6-month overal

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 201, a registration

Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--FDA grants Fast Track designation to VS-7375, an oral invest

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines f

Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers th

BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price tar

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.43) per share which beat the analyst consens

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.48) per share which beat the analyst consens

HC Wainwright & Co. analyst Andres Y. Maldonado assumes Verastem (NASDAQ:VSTM) with a Buy rat

Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product rev

The RAMP 203 trial in advanced KRAS G12C–mutated non-small cell lung cancer has been discontinued du

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C